List of Invokana drug patents

Invokana is owned by Janssen Pharms.

Invokana contains Canagliflozin.

Invokana has a total of 5 drug patents out of which 0 drug patents have expired.

Invokana was authorised for market use on 29 March, 2013.

Invokana is available in tablet;oral dosage forms.

Invokana can be used as reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day; treatment of type 2 diabetes mellitus, reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; treatment of type 2 diabetes mellitus; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients, treatment of type 2 diabetes mellitus; reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients.

The generics of Invokana are possible to be released after 11 May, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(4 years from now)

US7943582 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Feb, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222219 JANSSEN PHARMS Glucopyranoside compound
Apr, 2025

(2 years from now)

US10617668 JANSSEN PHARMS Pharmaceutical formulations
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Sep 27, 2022

Drugs and Companies using CANAGLIFLOZIN ingredient

Market Authorisation Date: 29 March, 2013

Treatment: Treatment of type 2 diabetes mellitus; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Reduction of risk of end stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 300 mg canagliflozin per day; Reduction of risk of major adverse cardiovascular events in the treatment of type 2 diabetes mellitus patients with 100 mg canagliflozin per day; Treatment of type 2 diabetes mellitus with 100 mg canagliflozin per day

Dosage: TABLET;ORAL

How can I launch a generic of INVOKANA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in